KIACTA™ is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, a rare disease that results from long-standing inflammatory conditions.

In May 2014, rights were obtained by BELLUS Health’s clinical development partner, Auven Therapeutics, to develop KIACTA™ as a treatment for sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs.

Auven Therapeutics is evaluating the potential use of KIACTA™ for the treatment of patients suffering from active pulmonary sarcoidosis. Auven Therapeutics has developed a clinical Phase 2/3 study protocol to evaluate the safety and efficacy of KIACTA™ in sarcoidosis and an investigational new drug application (IND) for this clinical study could be filed with the U.S. Food and Drug Administration (FDA) in the first quarter of 2017.

The sarcoidosis program is currently under review by Auven Therapeutics and a decision is expected to be made in the coming months.

Disease and Market

Sarcoidosis is a rare condition that causes small patches of red and swollen tissue - called granulomas - that can develop in multiple organs in the body, but mostly in the lungs and skin. The disease affects approximately 120,000 patients in the US alone and identification of an effective treatment is a major unmet medical need. Most patients with sarcoidosis recover, but approximately 30% develop chronic, debilitating disease. Mortality occurs in 1-5% of patients. There is no cure for sarcoidosis, and treatment options are limited and can have serious adverse effects.

Study

Auven Therapeutics has developed a clinical Phase 2/3 study protocol to evaluate the safety and efficacy of KIACTA™ in sarcoidosis and an investigational new drug application (IND) for this clinical study could be filed with the U.S. Food and Drug Administration (FDA) in the first quarter of 2017. In vitro study test results in sarcoidosis indicate that KIACTA™ may reduce SAA-induced inflammatory cytokine expression.

In May 2014, the rights to develop KIACTA™ as a treatment for chronic sarcoidosis were obtained by Auven Therapeutics from the Icahn School of Medicine at Mount Sinai Hospital in New York.

Partnership with Auven Therapeutics

BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. 

For more information about Auven Therapeutics, please see our About Us - KIACTATM Partner section.

Share this

Sign up for email alerts

Email Address *
 
Enter the code shown above.